Loading
The trial that showed anlotinib helps patients with lung cancer live longer after other treatments have failed, the basis of one of China's most used cancer pills.
439 patients randomised 2:1. Median overall survival 9.6 versus 6.3 months (hazard ratio 0.68) and progression-free survival 5.4 versus 1.4 months; published in JAMA Oncology 2018. NMPA approval May 2018. Anlotinib went on to approvals in sarcoma, small cell lung cancer and thyroid cancer and to dozens of combination trials with domestic PD-1 antibodies.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Shanghai Chest Hospital, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares Anlotinib and the tag china.
Shares Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag china.
Shares Non-small-cell lung cancer and the tag china.
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares Anti-angiogenic therapy and the tag china.